Open-Label, Multiple Ascending Dose Phase 1b/2a Study of the Safety and Tolerability of Intravitreal (IVT) EYC-0305 in Patients With Neovascular Age-Related Macular Degeneration
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
This Phase 1b/2a study will primarily investigate the safety and tolerability of EYC-0305 delivered by intravitreal (IVT) injection every 24 weeks in patients with neovascular (wet) age-related macular degeneration (AMD). The pharmacokinetics (PK) and immunogenicity of EYC-0305, and the effect on disease activity and vision will also be evaluated.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:
• Men or women 50 years and older with neovascular (wet) AMD meeting all study-specified eligibility criteria
• Willing and able to comply with clinic visits and study-related procedures
• Provide signed informed consent
Locations
United States
California
Beverly Hills, CA
RECRUITING
Beverly Hills
North Carolina
Wake Forest, NC
RECRUITING
Wake Forest
Pennsylvania
Erie, PA
RECRUITING
Erie
Texas
Bellaire, TX
RECRUITING
Bellaire
McAllen, TX
RECRUITING
Mcallen
The Woodlands, TX
RECRUITING
The Woodlands
Contact Information
Primary
Kim Reed, OD, FAAO
info@eyconis.com
1-866-392-6647
Backup
Karen Chu, MS
info@eyconis.com
1-866-392-6647
Time Frame
Start Date: 2026-05-19
Estimated Completion Date: 2028-05
Participants
Target number of participants: 30
Treatments
Experimental: EYC-0305 Dose Level 1
Experimental: EYC-0305 Dose Level 2
Experimental: EYC-0305 Dose Level 3
Experimental: EYC-0305 Dose Level 4
Related Therapeutic Areas
Sponsors
Leads: Eyconis INC.